BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12854955)

  • 1. Oncogenic mutations and packing defects in protein structure.
    Fernández A
    J Biomol Struct Dyn; 2003 Aug; 21(1):9-14. PubMed ID: 12854955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis and NMR spectroscopy of quail cysteine and glycine-rich protein CRP2 reveal an intrinsic segmental flexibility of LIM domains.
    Kloiber K; Weiskirchen R; Kräutler B; Bister K; Konrat R
    J Mol Biol; 1999 Oct; 292(4):893-908. PubMed ID: 10525413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants.
    Muraoka S; Shima F; Araki M; Inoue T; Yoshimoto A; Ijiri Y; Seki N; Tamura A; Kumasaka T; Yamamoto M; Kataoka T
    FEBS Lett; 2012 Jun; 586(12):1715-8. PubMed ID: 22584058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated conformations of the ras-gene-encoded p21 protein. 1. An energy-refined structure for the normal p21 protein complexed with GDP.
    Dykes DC; Brandt-Rauf P; Luster SM; Chung D; Friedman FK; Pincus MR
    J Biomol Struct Dyn; 1992 Jun; 9(6):1025-44. PubMed ID: 1637501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of guanosine triphosphate hydrolysis by Ras and Ras-GAP proteins as rationalized by ab initio QM/MM simulations.
    Grigorenko BL; Nemukhin AV; Shadrina MS; Topol IA; Burt SK
    Proteins; 2007 Feb; 66(2):456-66. PubMed ID: 17094109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics simulations of Gly-12-->Val mutant of p21(ras): dynamic inhibition mechanism.
    Futatsugi N; Tsuda M
    Biophys J; 2001 Dec; 81(6):3483-8. PubMed ID: 11721009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Zn2+ on DNA recognition and stability of the p53 DNA-binding domain.
    Duan J; Nilsson L
    Biochemistry; 2006 Jun; 45(24):7483-92. PubMed ID: 16768444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution structure of bovine pancreatic trypsin inhibitor with altered binding loop sequence.
    Czapinska H; Otlewski J; Krzywda S; Sheldrick GM; Jaskólski M
    J Mol Biol; 2000 Feb; 295(5):1237-49. PubMed ID: 10653700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro structure-function analysis of the beta-strand 326-333 of human p53.
    Chène P; Mittl P; Grütter M
    J Mol Biol; 1997 Nov; 273(4):873-81. PubMed ID: 9367778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.
    Mora P; Carbajo RJ; Pineda-Lucena A; Sánchez del Pino MM; Pérez-Payá E
    Proteins; 2008 Jun; 71(4):1670-85. PubMed ID: 18076077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural effect of the L16Q, K50E, and R53P mutations on homeodomain of pituitary homeobox protein 2.
    Rajasekaran M; Chen C
    Int J Biol Macromol; 2012 Oct; 51(3):305-13. PubMed ID: 22584078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.
    Al-Mulla F; Milner-White EJ; Going JJ; Birnie GD
    J Pathol; 1999 Mar; 187(4):433-8. PubMed ID: 10398103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutants without a functional tetramerisation domain are not oncogenic.
    Chène P; Bechter E
    J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
    Trulson JA; Millhauser GL
    Biopolymers; 1999 Mar; 49(3):215-24. PubMed ID: 9990839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linear free energy relationships in the intrinsic and GTPase activating protein-stimulated guanosine 5'-triphosphate hydrolysis of p21ras.
    Schweins T; Geyer M; Kalbitzer HR; Wittinghofer A; Warshel A
    Biochemistry; 1996 Nov; 35(45):14225-31. PubMed ID: 8916907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain.
    Butler JS; Loh SN
    Biochemistry; 2003 Mar; 42(8):2396-403. PubMed ID: 12600206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.